|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EIF1B |
Gene summary for EIF1B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EIF1B | Gene ID | 10289 |
| Gene name | eukaryotic translation initiation factor 1B | |
| Gene Alias | GC20 | |
| Cytomap | 3p22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | O60739 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10289 | EIF1B | CA_HPV_1 | Human | Cervix | CC | 1.28e-06 | -6.38e-02 | 0.0264 |
| 10289 | EIF1B | CA_HPV_3 | Human | Cervix | CC | 8.55e-03 | 1.75e-01 | 0.0414 |
| 10289 | EIF1B | CCI_1 | Human | Cervix | CC | 8.41e-11 | -5.37e-01 | 0.528 |
| 10289 | EIF1B | CCI_3 | Human | Cervix | CC | 6.06e-06 | -4.30e-01 | 0.516 |
| 10289 | EIF1B | CCII_1 | Human | Cervix | CC | 6.91e-20 | -5.37e-01 | 0.3249 |
| 10289 | EIF1B | Tumor | Human | Cervix | CC | 4.36e-04 | -2.91e-01 | 0.1241 |
| 10289 | EIF1B | AEH-subject1 | Human | Endometrium | AEH | 1.97e-08 | -3.23e-01 | -0.3059 |
| 10289 | EIF1B | AEH-subject2 | Human | Endometrium | AEH | 3.71e-11 | -3.39e-01 | -0.2525 |
| 10289 | EIF1B | AEH-subject3 | Human | Endometrium | AEH | 1.47e-14 | -3.74e-01 | -0.2576 |
| 10289 | EIF1B | AEH-subject4 | Human | Endometrium | AEH | 2.34e-03 | -2.70e-01 | -0.2657 |
| 10289 | EIF1B | AEH-subject5 | Human | Endometrium | AEH | 1.74e-05 | -3.53e-01 | -0.2953 |
| 10289 | EIF1B | EEC-subject1 | Human | Endometrium | EEC | 1.13e-10 | -3.30e-01 | -0.2682 |
| 10289 | EIF1B | EEC-subject2 | Human | Endometrium | EEC | 3.26e-20 | -4.81e-01 | -0.2607 |
| 10289 | EIF1B | EEC-subject3 | Human | Endometrium | EEC | 1.00e-36 | -3.30e-01 | -0.2525 |
| 10289 | EIF1B | EEC-subject4 | Human | Endometrium | EEC | 3.34e-04 | -2.48e-01 | -0.2571 |
| 10289 | EIF1B | EEC-subject5 | Human | Endometrium | EEC | 6.34e-07 | -3.18e-01 | -0.249 |
| 10289 | EIF1B | GSM5276934 | Human | Endometrium | EEC | 9.57e-06 | 2.12e-01 | -0.0913 |
| 10289 | EIF1B | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 3.73e-24 | -4.13e-01 | -0.1869 |
| 10289 | EIF1B | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 8.22e-30 | -3.51e-01 | -0.1875 |
| 10289 | EIF1B | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 3.58e-31 | -3.30e-01 | -0.1883 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000641710 | Cervix | CC | regulation of translation | 89/2311 | 468/18723 | 1.86e-05 | 3.46e-04 | 89 |
| GO:00064139 | Cervix | CC | translational initiation | 25/2311 | 118/18723 | 4.54e-03 | 2.75e-02 | 25 |
| GO:000641310 | Endometrium | AEH | translational initiation | 42/2100 | 118/18723 | 2.68e-12 | 4.67e-10 | 42 |
| GO:000641716 | Endometrium | AEH | regulation of translation | 94/2100 | 468/18723 | 1.14e-08 | 7.62e-07 | 94 |
| GO:00064467 | Endometrium | AEH | regulation of translational initiation | 25/2100 | 79/18723 | 8.99e-07 | 3.19e-05 | 25 |
| GO:000641315 | Endometrium | EEC | translational initiation | 42/2168 | 118/18723 | 7.65e-12 | 1.24e-09 | 42 |
| GO:000641717 | Endometrium | EEC | regulation of translation | 94/2168 | 468/18723 | 5.37e-08 | 2.88e-06 | 94 |
| GO:000644614 | Endometrium | EEC | regulation of translational initiation | 25/2168 | 79/18723 | 1.62e-06 | 5.03e-05 | 25 |
| GO:000641727 | Esophagus | HGIN | regulation of translation | 139/2587 | 468/18723 | 1.46e-19 | 7.98e-17 | 139 |
| GO:000641320 | Esophagus | HGIN | translational initiation | 55/2587 | 118/18723 | 7.33e-18 | 2.31e-15 | 55 |
| GO:000644610 | Esophagus | HGIN | regulation of translational initiation | 34/2587 | 79/18723 | 2.09e-10 | 1.97e-08 | 34 |
| GO:0006413110 | Esophagus | ESCC | translational initiation | 100/8552 | 118/18723 | 1.16e-18 | 1.25e-16 | 100 |
| GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
| GO:000644617 | Esophagus | ESCC | regulation of translational initiation | 65/8552 | 79/18723 | 2.04e-11 | 7.07e-10 | 65 |
| GO:000641312 | Liver | Cirrhotic | translational initiation | 76/4634 | 118/18723 | 8.36e-20 | 2.18e-17 | 76 |
| GO:000641712 | Liver | Cirrhotic | regulation of translation | 194/4634 | 468/18723 | 7.28e-16 | 8.79e-14 | 194 |
| GO:000644612 | Liver | Cirrhotic | regulation of translational initiation | 48/4634 | 79/18723 | 1.14e-11 | 7.14e-10 | 48 |
| GO:000641722 | Liver | HCC | regulation of translation | 287/7958 | 468/18723 | 8.79e-17 | 8.08e-15 | 287 |
| GO:000641322 | Liver | HCC | translational initiation | 94/7958 | 118/18723 | 1.39e-16 | 1.24e-14 | 94 |
| GO:000644622 | Liver | HCC | regulation of translational initiation | 62/7958 | 79/18723 | 6.85e-11 | 2.48e-09 | 62 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EIF1B | SNV | Missense_Mutation | novel | c.332N>G | p.His111Arg | p.H111R | O60739 | protein_coding | deleterious(0.01) | possibly_damaging(0.706) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| EIF1B | SNV | Missense_Mutation | novel | c.171N>T | p.Lys57Asn | p.K57N | O60739 | protein_coding | tolerated(0.1) | probably_damaging(0.976) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| EIF1B | SNV | Missense_Mutation | novel | c.41N>T | p.Ala14Val | p.A14V | O60739 | protein_coding | deleterious(0.02) | benign(0.003) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| EIF1B | SNV | Missense_Mutation | novel | c.238N>A | p.Gly80Arg | p.G80R | O60739 | protein_coding | deleterious(0.03) | possibly_damaging(0.572) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| EIF1B | SNV | Missense_Mutation | novel | c.171N>T | p.Lys57Asn | p.K57N | O60739 | protein_coding | tolerated(0.1) | probably_damaging(0.976) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| EIF1B | SNV | Missense_Mutation | novel | c.26N>A | p.Ser9Tyr | p.S9Y | O60739 | protein_coding | deleterious(0.02) | benign(0.033) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| EIF1B | SNV | Missense_Mutation | novel | c.289N>A | p.Leu97Ile | p.L97I | O60739 | protein_coding | deleterious(0.03) | possibly_damaging(0.688) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| EIF1B | SNV | Missense_Mutation | novel | c.285G>T | p.Gln95His | p.Q95H | O60739 | protein_coding | deleterious(0.03) | benign(0.015) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| EIF1B | SNV | Missense_Mutation | c.195N>T | p.Lys65Asn | p.K65N | O60739 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| EIF1B | SNV | Missense_Mutation | novel | c.200N>C | p.Phe67Ser | p.F67S | O60739 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |